Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:AMPE NASDAQ:CARM NASDAQ:PTIX NASDAQ:TCON On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAMPEAmpio Pharmaceuticals$0.18$0.18$0.00▼$0.64$208K5.962,326 shsN/ACARMCarisma Therapeutics$0.01+13.3%$0.01$0.00▼$0.56$213K-9.3473,703 shs11,491 shsPTIXAtrinsic$0.22$0.42$0.14▼$6.20$390K1.0131,806 shs6 shsTCONTRACON Pharmaceuticals$0.03$0.04$0.00▼$14.75$110K1.37120,908 shsN/A7 Stocks That Could Lead the Next Market BoomTesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAMPEAmpio Pharmaceuticals0.00%0.00%0.00%-27.50%+6,681.48%CARMCarisma Therapeutics+7.14%-21.05%-55.00%+1,025.00%-98.83%PTIXAtrinsic0.00%-17.17%-52.09%-70.21%-93.54%TCONTRACON Pharmaceuticals0.00%0.00%0.00%0.00%0.00%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAMPEAmpio Pharmaceuticals$0.18$0.18$0.00▼$0.64$208K5.962,326 shsN/ACARMCarisma Therapeutics$0.01+13.3%$0.01$0.00▼$0.56$213K-9.3473,703 shs11,491 shsPTIXAtrinsic$0.22$0.42$0.14▼$6.20$390K1.0131,806 shs6 shsTCONTRACON Pharmaceuticals$0.03$0.04$0.00▼$14.75$110K1.37120,908 shsN/A7 Stocks That Could Lead the Next Market BoomTesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAMPEAmpio Pharmaceuticals0.00%0.00%0.00%-27.50%+6,681.48%CARMCarisma Therapeutics+7.14%-21.05%-55.00%+1,025.00%-98.83%PTIXAtrinsic0.00%-17.17%-52.09%-70.21%-93.54%TCONTRACON Pharmaceuticals0.00%0.00%0.00%0.00%0.00%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAMPEAmpio Pharmaceuticals 0.00N/AN/AN/ACARMCarisma Therapeutics 2.00Hold$1.0019,507.84% UpsidePTIXAtrinsic 1.00SellN/AN/ATCONTRACON Pharmaceuticals 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownCompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAMPEAmpio PharmaceuticalsN/AN/AN/AN/A$4.04 per shareN/ACARMCarisma Therapeutics$10.77M0.02N/AN/A($0.67) per share-0.01PTIXAtrinsicN/AN/AN/AN/A$1.96 per shareN/ATCONTRACON Pharmaceuticals$12.05M0.01$1.61 per share0.02($0.37) per share-0.09Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAMPEAmpio Pharmaceuticals-$8.63M-$11.01N/AN/AN/AN/AN/AN/AN/ACARMCarisma Therapeutics-$60.48M$0.730.01N/AN/A-254.28%N/A-192.17%N/APTIXAtrinsic-$5.53M-$3.45N/AN/AN/AN/AN/A-379.72%8/18/2026 (Estimated)TCONTRACON Pharmaceuticals-$3.59M$3.730.01N/AN/AN/A-237.65%57.29%N/ALatest TCON, PTIX, CARM, and AMPE EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/18/2026N/APTIXAtrinsic-$4.48N/AN/AN/AN/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthAMPEAmpio PharmaceuticalsN/AN/AN/AN/AN/ACARMCarisma TherapeuticsN/AN/AN/AN/AN/APTIXAtrinsicN/AN/AN/AN/AN/ATCONTRACON PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAMPEAmpio PharmaceuticalsN/AN/AN/ACARMCarisma TherapeuticsN/A0.480.48PTIXAtrinsicN/A0.290.29TCONTRACON PharmaceuticalsN/A0.660.66Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAMPEAmpio Pharmaceuticals5.73%CARMCarisma Therapeutics44.27%PTIXAtrinsic7.97%TCONTRACON Pharmaceuticals11.61%Insider OwnershipCompanyInsider OwnershipAMPEAmpio Pharmaceuticals3.30%CARMCarisma Therapeutics6.90%PTIXAtrinsic8.00%TCONTRACON Pharmaceuticals5.27%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAMPEAmpio Pharmaceuticals201.14 million1.10 millionNo DataCARMCarisma Therapeutics2041.85 million38.91 millionNo DataPTIXAtrinsic21.81 million1.78 millionNot OptionableTCONTRACON Pharmaceuticals203.41 million3.23 millionNo DataTCON, PTIX, CARM, and AMPE HeadlinesRecent News About These CompaniesTRACON Pharma (OTC:TCON) Stock, Short Interest ReportOctober 5, 2024 | benzinga.comTRACON Pharmaceuticals Announces it Will Wind Down OperationsJuly 30, 2024 | globenewswire.comTRACON Announces Publication in Clinical Cancer Research of Phase 2 Clinical Data for TRC102, a DNA Damage Repair Inhibitor, in Recurrent Glioblastoma PatientsJune 11, 2024 | globenewswire.comTRACON Pharmaceuticals Inc (NASDAQ:TCON) Stock Price Settled at $1.49: What’s Resulting?May 27, 2024 | bovnews.comBTRACON Pharmaceuticals, Inc. (NASDAQ:TCON) Q1 2024 Earnings Call TranscriptMay 15, 2024 | msn.comQ1 2024 TRACON Pharmaceuticals Inc Earnings CallMay 15, 2024 | finance.yahoo.comTRACON Pharmaceuticals Inc (TCON) Q1 2024 Earnings Call Transcript Highlights: Strategic ...May 15, 2024 | finance.yahoo.comTCON Stock Earnings: TRACON Pharma Misses EPS for Q1 2024May 14, 2024 | investorplace.comTRACON Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Corporate UpdateMay 14, 2024 | finance.yahoo.comTracon: Q1 Earnings SnapshotMay 14, 2024 | timesunion.comTTRACON Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Corporate UpdateMay 14, 2024 | globenewswire.comTRACON to Report First Quarter 2024 Financial Results and Provide Corporate Update on May 14, 2024May 7, 2024 | globenewswire.comTRACON Pharmaceuticals IncApril 26, 2024 | money.usnews.comBuy Rating Reaffirmed for TRACON Pharmaceuticals Post-Reverse Split and Envafolimab Valuation UpdateApril 10, 2024 | markets.businessinsider.comTRACON announces 1-for-20 reverse stock splitApril 10, 2024 | uk.investing.comWall Street Favorites: 3 Penny Stocks With Strong Buy Ratings for April 2024April 10, 2024 | investorplace.comShares of Tracon Pharmaceuticals Tumble 22% on Reverse SplitApril 8, 2024 | marketwatch.comTRACON Pharmaceuticals, Inc.: TRACON Pharmaceuticals Announces Reverse Stock SplitApril 8, 2024 | finanznachrichten.deTRACON Pharmaceuticals Announces Reverse Stock SplitApril 8, 2024 | globenewswire.comBuy Rating Affirmed for TRACON Pharmaceuticals Amid Promising Envafolimab Trial OutlookApril 4, 2024 | markets.businessinsider.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesSK Hynix’s Nasdaq Listing Could Reset the AI Memory TradeBy Thomas Hughes | July 7, 20265 Tech Stocks to Buy on the July PullbackBy Thomas Hughes | June 29, 2026Rocket Lab’s Stock Drop Comes With a Bullish TwistBy Ryan Hasson | July 10, 2026The SpaceX Sell-Off May Be More Than a Market OverreactionBy Jeffrey Neal Johnson | June 24, 2026This Single Factor Is Holding Back Carvana’s Disruptive EdgeBy Chris Markoch | June 26, 2026TCON, PTIX, CARM, and AMPE Company DescriptionsAmpio Pharmaceuticals NYSE:AMPE$0.18 0.00 (0.00%) As of 07/22/2026Ampio Pharmaceuticals, Inc., a biopharmaceutical company, develops therapies for the treatment of osteoarthritis of the knee (OAK) in the United States. It develops OA-201, a small molecule formulation for the treatment of OAK pain. The company is headquartered in Englewood, Colorado.Carisma Therapeutics NASDAQ:CARM$0.0051 +0.00 (+13.33%) As of 03:24 PM EasternCarisma Therapeutics, Inc., a clinical-stage cell therapy company, focuses on discovering and developing immunotherapies to treat cancer and other serious diseases in the United States. The company's ex vivo CAR-M cell therapies include CT-0508, a CAR-macrophage, which is in Phase 1 clinical trial to treat solid tumors; CT-0525, a CAR-monocyte that is in Phase 1 clinical trial to treat solid tumors; and CT-1119, a mesothelin-targeted CAR-Monocyte that is in pre-clinical stage to treat patients with advanced mesothelin-positive solid tumors, including lung cancer, mesothelioma, pancreatic cancer, ovarian cancer, and others. It is also developing in vivo CAR-M cell therapies in collaboration with Moderna Therapeutics to address multiple cancer targets; and multiple assets for the potential treatment of diseases beyond oncology, including fibrosis and other immunologic and inflammatory diseases. The company was formerly known as CARMA Therapeutics Inc. and changed its name to Carisma Therapeutics, Inc. in May 2017. The company was founded in 2016 and is headquartered in Philadelphia, Pennsylvania.Atrinsic NASDAQ:PTIX$0.22 0.00 (0.00%) As of 07/22/2026Protagenic Therapeutics, Inc., a biopharmaceutical company, engages in the discovery and development of therapeutics to treat stress-related neuropsychiatric and mood disorders. Its lead compound comprises PT00114, a synthetic form of teneurin carboxy-terminal associated peptide, an endogenous brain signaling peptide that can dampen overactive stress responses. Protagenic Therapeutics, Inc. is headquartered in New York, New York.TRACON Pharmaceuticals NASDAQ:TCONTRACON Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel targeted therapeutics for cancer in the United States. Its clinical stage products include envafolimab (KN035), a PD-L1 single-domain antibody for the treatment of refractory soft tissue sarcoma; and YH001, an investigational humanized cytotoxic T-lymphocyte-associated protein 4 IgG1 monoclonal antibody that is in Phase I clinical trial for the treatment of various cancer indications. The company's clinical stage products also include TRC102, a small molecule that is in Phase II clinical trial for the treatment of mesothelioma, and in Phase I clinical trial to treat solid tumors, lung cancer, and glioblastoma; and TJ004309, a CD73 antibody that is in Phase I clinical development for the treatment of solid tumors. In addition, it is developing bispecific antibodies, which are in preclinical stage. It has collaboration and license agreements with 3D Medicines Co., Ltd. and Jiangsu Alphamab Biopharmaceuticals Co., Ltd. for the development of envafolimab; I-Mab Biopharma for the development of CD73 antibody TJ004309 and bispecific antibodies; and cooperative research and development agreement with National Cancer Institute. The company was formerly known as Lexington Pharmaceuticals, Inc. and changed its name to TRACON Pharmaceuticals, Inc. in March 2005. TRACON Pharmaceuticals, Inc. was incorporated in 2004 and is headquartered in San Diego, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas AMD’s $5 Billion Anthropic Deal Could Redraw the AI Chip Battle Alphabet Crushed Earnings, But One Number Spooked the Market Premium Retail’s Stress Test Is Separating Winners From Losers GE Vernova Just Sent a Mixed AI Signal to Investors Otis Took Another Guidance Cut—But the Story Isn't Over Philip Morris Trimmed Guidance, But Its Growth Story Looks Unshaken The 2026 Blueprint: 6 Stocks for a Brand New Portfolio Cementing the Sky: Why NVIDIA’s Bet on Nebius Matters Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
